Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13049101 | 0.77 | HSD11B1 (0.31) | PTGS2HSD11B1 | |
| SCHEMBL3560853 | 0.76 | LMNA (0.43) | PTGS2 | |
| SCHEMBL3564109 | 0.74 | MMP2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL13343547 | 0.70 | ELANE (0.41) | — | |
| SCHEMBL5238331 | 0.68 | HTR2A (0.33) | HSD11B1 | |
| SCHEMBL5198243 | 0.68 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL3394959 | 0.68 | PTGS2 (0.47) | PTGS2PTGS1 | |
| SCHEMBL3552683 | 0.67 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL608235 | 0.66 | TACR1 (0.33) | HSD11B1 | |
| SCHEMBL19433471 | 0.65 | HTR2A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010142741-A1 | PHENYLPYRIDYLPYRIDONES FOR USE AS ANTIMALARIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674808-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-7629365-B2 | antimalarial agent; 3-chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H )-pyridinone | GLAXO GROUP LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1862459-A1 | Novel heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021073-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP3A4, G6PD | PTGS2 1454/4885HSD11B1 2314/4885PTGS1 1209/4885 |
| US-20070281977-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CYP4B1, CYP2C19, CYP3A4 | PTGS2 1115/4885HSD11B1 1682/4885PTGS1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.